{"url_path":"/sec/kymr/8-k/2026-06-24/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1815442/0001193125-26-281051-index.html","accession_number":"0001193125-26-281051","cik":"0001815442","ticker":"KYMR","issuer_name":"Kymera Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1815442/0001193125-26-281051-index.html","primary_entity_key":"0001815442","primary_entity_name":"Kymera Therapeutics, Inc."},"word_count":399,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders\n\nKymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 24, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2026. The final voting results are set forth below.\n\nProposal 1 – Election of Class III Director Nominees\n\nThe shareholders of the Company elected Bruce Booth, D.Phil., Nello Mainolfi, Ph.D., John Maraganore, Ph.D. and Elena Ridloff, CFA as Class III directors of the Company, each to hold office for a three-year term ending at the annual meeting of shareholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal. The results of the shareholders’ vote with respect to the election of the Class III directors were as follows:\n\n \n\n \n  \nVotes\nFor\n  \nVotes\nWithheld\n  \nBroker\nNon-Votes\n\nBruce Booth, D.Phil.\n\n  \n71,962,459\n  \n5,430,527\n  \n1,707,176\n\nNello Mainolfi, Ph.D.\n\n  \n73,411,316\n  \n3,981,670\n  \n1,707,176\n\nJohn Maraganore, Ph.D.\n\n  \n72,501,958\n  \n4,891,028\n  \n1,707,176\n\nElena Ridloff, CFA\n\n  \n72,453,404\n  \n4,939,582\n  \n1,707,176\n\nProposal 2 – Non-Binding, Advisory Vote on Compensation of the Company’s Named Executive Officers\n\nThe shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The results of the shareholders’ non-binding, advisory vote with respect to such approval were as follows:\n\n \n\nVotes\n\nFor\n\n \n\nVotes\n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker\nNon-Votes\n\n74,903,687\n \n2,462,732\n \n26,567\n \n1,707,176\n\nProposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm\n\nThe shareholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the shareholders’ vote with respect to such ratification were as follows:\n\n \n\nVotes\n\nFor\n\n \n\nVotes\n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker\nNon-Votes\n\n79,043,801\n\n \n\n38,128\n\n \n\n18,233\n\n \n\n0\n\nNo other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nKymera Therapeutics, Inc.\n\nDate: June 24, 2026\n \n\n \nBy:\n \n\n/s/ Nello Mainolfi\n\n \n\n \n\n \nNello Mainolfi, Ph.D.\n\n \n\n \n\n \nPresident and Chief Executive Officer"}